CN109328061A - 用于治疗角化过度症的组合物 - Google Patents

用于治疗角化过度症的组合物 Download PDF

Info

Publication number
CN109328061A
CN109328061A CN201780038116.6A CN201780038116A CN109328061A CN 109328061 A CN109328061 A CN 109328061A CN 201780038116 A CN201780038116 A CN 201780038116A CN 109328061 A CN109328061 A CN 109328061A
Authority
CN
China
Prior art keywords
composition
selenium
ophthalmic applications
keratin
eyelid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780038116.6A
Other languages
English (en)
Chinese (zh)
Inventor
亚伊尔·阿尔斯特
奥默·拉法尔里
希蒙·艾姆萨勒姆
多伦·弗里德曼
扎卡尔·努德尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Al Zu La Eye Co Ltd
Original Assignee
Al Zu La Eye Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Al Zu La Eye Co Ltd filed Critical Al Zu La Eye Co Ltd
Publication of CN109328061A publication Critical patent/CN109328061A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780038116.6A 2016-04-19 2017-04-18 用于治疗角化过度症的组合物 Pending CN109328061A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662324795P 2016-04-19 2016-04-19
US62/324,795 2016-04-19
PCT/IB2017/000638 WO2017182885A2 (en) 2016-04-19 2017-04-18 Compositions for the treatment of hyperkeratosis disorders

Publications (1)

Publication Number Publication Date
CN109328061A true CN109328061A (zh) 2019-02-12

Family

ID=60115757

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780038116.6A Pending CN109328061A (zh) 2016-04-19 2017-04-18 用于治疗角化过度症的组合物

Country Status (10)

Country Link
US (2) US20200179305A1 (enExample)
EP (1) EP3445352A4 (enExample)
JP (1) JP2019513775A (enExample)
KR (1) KR20180133913A (enExample)
CN (1) CN109328061A (enExample)
AU (1) AU2017252026A1 (enExample)
CA (1) CA3020713A1 (enExample)
IL (1) IL262348A (enExample)
MA (1) MA44737A (enExample)
WO (1) WO2017182885A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CN108472312A (zh) * 2015-09-28 2018-08-31 阿祖拉眼科有限公司 用于增加睑板腺脂质分泌物的含硫醇及二硫化物的药剂
CA3019349A1 (en) 2016-04-14 2017-10-19 Azura Ophthalmics Ltd. Selenium disulfide compositions for use in treating meibomian gland dysfunction
US12016849B2 (en) 2016-10-12 2024-06-25 Bonafide Health, Llc Magnesium picolinate compositions and methods of use
CN108840904B (zh) * 2018-07-12 2022-03-04 江西中科硒谷功能农业发展有限公司 一种从烟叶中提取硒蛋白质的方法
JP7142286B2 (ja) * 2018-07-13 2022-09-27 慶應義塾 セレン含有アミノ酸を含む糖鎖－ポリペプチド複合体、および、その医薬用途
WO2020212755A1 (en) * 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
JP7700045B2 (ja) 2019-04-18 2025-06-30 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
AU2020259997B2 (en) 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
US20200345768A1 (en) * 2019-05-01 2020-11-05 Nutrition 21, Llc Zinc picolinate, magnesium picolinate and selenium methionine compositions and methods of use
CA3166357A1 (en) 2020-01-10 2021-07-15 Azura Ophthalmics Ltd. Instructions for composition and sensitivity
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
CN101132693A (zh) * 2004-08-02 2008-02-27 萨米莱布斯有限公司 用于控制过度增生性皮肤病的组合物以及方法
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495158B1 (en) * 2001-01-19 2002-12-17 Lec Tec Corporation Acne patch
US20030224028A1 (en) * 2002-05-13 2003-12-04 Societe L'oreal S.A. Metal complexes for promoting skin desquamation and/or stimulating epidermal renewal
US20050065091A1 (en) * 2003-09-18 2005-03-24 Gholam Peyman Stabilized ocular solutions
WO2005079143A2 (en) * 2004-02-19 2005-09-01 Occell Inc. Topical formulations for the treatment of skin conditions
EP1915998A4 (en) * 2005-06-22 2009-11-18 Kowa Co PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST HORNHAUT / BINDEHAUT DISEASES
AU2010303166A1 (en) * 2009-10-10 2012-05-24 Eleven Biotherapeutics, Inc. IL-17 family cytokine compositions and uses
US8765725B2 (en) * 2012-05-08 2014-07-01 Aciex Therapeutics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof
CN105025906B (zh) * 2012-12-21 2020-08-25 阿克生物科技公司 来自鱼孵化液的化妆品组合物
US9463201B2 (en) * 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011067A (en) * 1999-06-11 2000-01-04 Thione International, Inc. Antioxidant composition for the treatment of psoriasis and related diseases
US20020127256A1 (en) * 2001-03-01 2002-09-12 Howard Murad Compositions and methods for treating dermatological disorders
CN101132693A (zh) * 2004-08-02 2008-02-27 萨米莱布斯有限公司 用于控制过度增生性皮肤病的组合物以及方法
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
姜涌等: "《临床医学概要》", 31 August 2015, 第四军医大学出版社 *
李伯埙: "《皮肤病临床与组织病理学》", 31 January 2015, 世界图书西安出版公司 *
杜锡贤: "《疔疮痈毒中西医特色治疗》", 31 May 2011, 人民军医出版社 *
沙翔垠: "《眼科学》", 30 April 2013, 人民军医出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116635032A (zh) * 2020-10-21 2023-08-22 阿祖拉眼科有限公司 用于治疗眼部病症的化合物和方法

Also Published As

Publication number Publication date
AU2017252026A1 (en) 2018-11-08
EP3445352A2 (en) 2019-02-27
MA44737A (fr) 2021-04-07
CA3020713A1 (en) 2017-10-26
US20230013824A1 (en) 2023-01-19
EP3445352A4 (en) 2019-12-11
WO2017182885A3 (en) 2017-12-14
US20200179305A1 (en) 2020-06-11
IL262348A (en) 2018-11-29
KR20180133913A (ko) 2018-12-17
JP2019513775A (ja) 2019-05-30
WO2017182885A2 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN109328061A (zh) 用于治疗角化过度症的组合物
US12048707B2 (en) Compositions and methods for the treatment of meibomian gland dysfunction
JP7138694B2 (ja) マイボーム腺の脂質分泌を増加させるためのチオールおよびジスルフィド含有薬剤
KR102541236B1 (ko) 마이봄샘 지질 분비 증가를 위한 작용제
CZ200136A3 (cs) Vitamín E a jeho estery pro použití při lokální léčbě onemocnění sliznice
Pasricha et al. Illustrated textbook of dermatology
US20250360076A1 (en) Compositions containing plant mucilage
Jiyad et al. Handbook of Skin Disease Management
Hazen Diseases of the Skin
Nolting et al. Onychomycoses: local antimycotic treatment
CN109152755A (zh) 用于儿童早期应用的羧酸
HK40004310A (en) Compositions for the treatment of hyperkeratosis disorders
Amundson et al. The skin and subcutaneous tissues
Fimiani et al. Neonatal Skin Disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40004310

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20190212

RJ01 Rejection of invention patent application after publication